- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05400512
Mejora cognitiva en la depresión (el estudio COG-D)
Neuromodulación no invasiva para mejorar la remediación cognitiva dirigida en adultos mayores con depresión
This study will investigate whether transcranial direct current stimulation (tDCS) enhances the effects of computerized cognitive training in older adults with recurrent depression (2 or more lifetime episodes; either current or within past 3 years).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The purpose of this study is to determine whether the addition of active tDCS to computerized cognitive remediation (nCCR) enhances brain activity and cognitive functions in older adults with recurrent depression to a greater degree than nCCR with sham stimulation. The investigators will randomize 20 elderly depressed outpatients to either double-blinded active or sham bifrontal tDCS plus daily nCCR over 4-weeks. Multimodal MRI (focused on the cognitive control network; CCN) and psychiatric and neuropsychological evaluations will be obtained at baseline and following intervention completion. Long-term CCN cognitive effects will be explored 3-months post-intervention via cognitive assessments.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37212
- Vanderbilt University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 60+ years
- Diagnosis of a current or past (within last 3 years) depressive episode (e.g., Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD)) using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
- In total, participants must have 2 or more lifetime depressive episodes to be considered "recurrent"
- Either stable antidepressant regimen for at least 6 weeks or no current antidepressant treatment
- Evidence of subjective cognitive complaints on the Everyday Cognition Scale (ECog)
- English fluency
Exclusion criteria:
- Other Axis I psychiatric conditions via the DSM-5, except for anxiety symptoms occurring in a depressive episode
- Acute suicidality on clinical evaluation
- Acute grief
- History of alcohol use disorder or substance use disorder in last 12 months
- Currently taking medications that would significantly interact with tDCS effects (such as sodium channel blockers or anticonvulsants)
- Neurological disorders (e.g., dementia, stroke, seizures, traumatic brain injury, Parkinson's disease)
- Montreal Cognitive Assessment (MoCA) score < 23
- Primary amnestic cognitive profile (>1.5 standard deviations (SDs) below demographically-adjusted mean on National Alzheimer's Coordinating Center (NACC) memory measures in context of otherwise normal cognitive profile)
- Any physical or intellectual disability affecting ability to complete assessments
- Unstable medical illness needing urgent treatment
- MRI contraindications
- Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last 2 months
- Current involvement in psychotherapy
- Current involvement in other research studies (including but not limited to: neuromodulation [TMS or tDCS] or investigational drug studies)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cognitive Training + Active Stimulation
This arm receives cognitive training combined with active tDCS. |
Computerized cognitive training targeting the underlying cerebral networks associated with depression. A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system). |
|
Experimental: Cognitive Training + Sham Stimulation
This arm receives cognitive training combined with sham tDCS. |
Computerized cognitive training targeting the underlying cerebral networks associated with depression. Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Task-based fMRI Activation Within the Cognitive Control Network During the N-back Task
Periodo de tiempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
MRI scans were performed at baseline (T1) and after completion of the intervention (4 to 6 weeks later; T2). MRI measured Cognitive Control Network function, operationalized as change in n-back functional MRI response in the anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), and the posterior parietal cortex (PPC) regions of interest. The n-back functional MRI response was calculated as the activation difference (beta values) between 2-back and 0-back conditions of the n-back. Higher scores indicate more activation during the 2-back condition compared to the 0-back condition. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
N-back Behavioral Performance (Accuracy)
Periodo de tiempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Target accuracy data on the n-back were extracted for each n-back condition (2-back and 0-back). Higher scores for the metrics indicated better accuracy. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
N-back Behavioral Performance (Response Time)
Periodo de tiempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Target response time data on the n-back were extracted for each n-back condition (2-back and 0-back). Lower scores indicate faster response times. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
NIH Examiner Scores
Periodo de tiempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Computerized neuropsychological battery to assess range of executive functions. The Executive Composite represents overall executive function performance across multiple neuropsychological measures. Item Response Theory (IRT) Empirical Bayes scoring based on the saved parameters from the 3 factors (Working Memory, Cognitive Control, Fluency) are used to generate scores, which are not a norm-referenced measure and are not adjusted for age. The composite is presented in the original metric used in the IRT algorithm. Scores range from -1.50 to 1.52. Higher scores mean better executive function. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
California Verbal Learning Test, 2nd Edition (CVLT-2) Scores
Periodo de tiempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
The California Verbal Learning Test, 2nd edition (CVLT-2) is a standardized measure of verbal learning and memory. Raw scores are obtained and converted to age and sex-adjusted z-scores, with 0 indicating population average. Positive values indicate of better than average learning and memory performances. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Montgomery Asberg Depression Rating Scale (MADRS) Scores)
Periodo de tiempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Depression rating scale that ranges from 0-60, with higher scores indicating greater depressive symptom severity. For percent change, post-intervention (T2) was compared to baseline (T1), with higher negative values indicating greater decrease in depressive symptoms at T2 compared to baseline. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sarah M. Szymkowicz, PhD, Vanderbilt University Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Síntomas de comportamiento
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Signos y síntomas
- Depresión
- Manifestaciones neuroconductuales
- Terapéutica
- Atención al paciente
- Servicios de salud
- Instalaciones de atención médica Fuerza laboral y servicios
- Disciplinas y actividades de comportamiento
- Rehabilitación
- Cuidado por los convalecientes
- Continuidad de la atención al paciente
- Terapia de estimulación eléctrica
- Terapia convulsiva
- Terapias somáticas psiquiátricas
- Electrochoque
- Técnicas psicológicas
- Rehabilitación neurológica
- Estimulación de corriente continua transcraneal
- Entrenamiento cognitivo
Otros números de identificación del estudio
- 220283
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .